The completed phase II trial evaluated a chemotherapy-sparing neoadjuvant approach for postmenopausal women with HR-positive, HER2-positive disease.
The phase II TOUCH trial evaluated whether a targeted and endocrine combination could serve as an alternative to a paclitaxel-based neoadjuvant regimen.
The strategy reflects continuing interest in reducing chemotherapy exposure while preserving antitumor activity in selected patients.